Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection
- PMID: 33471984
- PMCID: PMC7844860
- DOI: 10.1056/NEJMe2034495
Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection
Comment on
-
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17. N Engl J Med. 2021. PMID: 33332778 Free PMC article. Clinical Trial.
Similar articles
-
Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection.New Microbiol. 2021 Jul;44(3):135-144. New Microbiol. 2021. PMID: 34783348 Review.
-
[SARS-CoV-2 neutralizing monoclonal antibodies: a potential breakthrough in the early treatment of Covid-19 in high-risk patients].Ned Tijdschr Geneeskd. 2021 Oct 7;165:D6173. Ned Tijdschr Geneeskd. 2021. PMID: 34854645 Dutch.
-
[SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies: a review].Sheng Wu Gong Cheng Xue Bao. 2022 Sep 25;38(9):3173-3193. doi: 10.13345/j.cjb.220328. Sheng Wu Gong Cheng Xue Bao. 2022. PMID: 36151792 Review. Chinese.
-
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13. Microbiol Spectr. 2021. PMID: 34643438 Free PMC article.
-
Realizing the Potential of Anti-SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management.JAMA. 2022 Feb 1;327(5):427-429. doi: 10.1001/jama.2021.19994. JAMA. 2022. PMID: 35029644 No abstract available.
Cited by
-
Neonatal sepsis and transient immunodeficiency: Potential for novel immunoglobulin therapies?Front Immunol. 2022 Oct 18;13:1016877. doi: 10.3389/fimmu.2022.1016877. eCollection 2022. Front Immunol. 2022. PMID: 36330515 Free PMC article. Review.
-
Development and Validation of the RCOS Prognostic Index: A Bedside Multivariable Logistic Regression Model to Predict Hypoxaemia or Death in Patients with SARS-CoV-2 Infection.Interdiscip Perspect Infect Dis. 2022 Apr 20;2022:2360478. doi: 10.1155/2022/2360478. eCollection 2022. Interdiscip Perspect Infect Dis. 2022. PMID: 35464253 Free PMC article.
-
Computer-aided discovery, design, and investigation of COVID-19 therapeutics.Tzu Chi Med J. 2022 Mar 28;34(3):276-286. doi: 10.4103/tcmj.tcmj_318_21. eCollection 2022 Jul-Sep. Tzu Chi Med J. 2022. PMID: 35912059 Free PMC article. Review.
-
Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis.PeerJ. 2023 May 8;11:e15344. doi: 10.7717/peerj.15344. eCollection 2023. PeerJ. 2023. PMID: 37180576 Free PMC article.
-
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions.Cell Rep Med. 2021 Jun 15;2(6):100313. doi: 10.1016/j.xcrm.2021.100313. Epub 2021 May 21. Cell Rep Med. 2021. PMID: 34056628 Free PMC article.
References
-
- Johns Hopkins University. The Center for Systems Science and Engineering (CSSE) COVID-19 Dashboard (https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594...).
-
- Jones BE, Brown-Augsburger PL, Corbett KS, et al. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. October 1, 2020 (https://www.biorxiv.org/content/10.1101/2020.09.30.318972v1). preprint.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical